| DIRECT COMPETITOR COMPARISON | |
| MRNA | EMIS.OB | JNJ | SKYEY.PK | Industry | | Market Cap: | 34.35M | 28.19M | 174.65B | N/A | 99.24M | | Employees: | 45 | 20 | 118,700 | N/A | 65 | | Qtrly Rev Growth (yoy): | -84.20% | N/A | -5.30% | N/A | 19.70% | | Revenue (ttm): | 14.71M | 5.00K | 60.53B | N/A | 14.01M | | Gross Margin (ttm): | -46.31% | 100.00% | 71.08% | N/A | 65.67% | | EBITDA (ttm): | -13.71M | -15.43M | 19.05B | N/A | -12.30M | | Oper Margins (ttm): | -111.05% | -322,640.00% | 26.94% | N/A | -137.11% | | Net Income (ttm): | -19.56M | -21.34M | 12.77B | N/A | N/A | | EPS (ttm): | -0.558 | -0.673 | 4.579 | N/A | -0.32 | | P/E (ttm): | N/A | N/A | 13.82 | N/A | 16.76 | | PEG (5 yr expected): | N/A | N/A | 1.86 | N/A | 1.32 | | P/S (ttm): | 2.47 | 5637.38 | 2.88 | N/A | 9.68 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.40 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | JNJ | | Deere Keeps Plowing
Thu 12:20pm -
at Investopedia | | • | JNJ | | Theravance, Inc.: Wait to Buy on Dip
Thu 6:19am -
at Seeking Alpha | | • | JNJ | | Health Care Winners
Thu 6:06am -
at Forbes.com | | • | JNJ | | FDA grants full approval to J&J's HIV drug
Wed, Nov 25 -
AP | | • | JNJ | | Turning to Widow and Orphan Stocks
Wed, Nov 25 -
at Barrons.com | | • | JNJ | | Novartis Didn't Know JAK, Until Now
Wed, Nov 25 -
at Motley Fool | | • | EMIS.OB | | Emisphere Technologies to Present at the New York Society of Security Analysts' 13th Annual Biotech & Specialty Pharma Investment Conference
Tue, Nov 24 -
Business Wire | | • | EMIS.OB | | NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
Fri, Nov 20 -
Business Wire | | • | SKYEY.PK | | Skyepharma PLC - Board Change
Wed, Nov 18 -
Marketwire | | • | EMIS.OB | | EMISPHERE TECHNOLOGIES INC Files SEC form 8-K, Change in Directors or Principal Officers
Mon, Nov 16 -
EDGAR Online | | • | EMIS.OB | | EMISPHERE TECHNOLOGIES INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | SKYEY.PK | | Skyepharma PLC - Interim Management Statement
Thu, Nov 12 -
Marketwire | | • | EMIS.OB | | EMISPHERE TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition
Mon, Nov 9 -
EDGAR Online | | • | SKYEY.PK | | SkyePharma: flutiform Phase III study complete
Mon, Nov 2 -
at MarketWatch | | • | SKYEY.PK | | Flutiform EU Clinical Trial Successfully Completed
Mon, Nov 2 -
Marketwire | | • | SKYEY.PK | | SkyePharma: Asthma drug needs more clinical work
Tue, Sep 1 -
at MarketWatch | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
0.0474 (5.33%) 
Competitors
